Screener
Neurocrine Biosciences NBIX Gain (loss) on disposal of assets
Gain (loss) on disposal of assets at other companies
Other financials
Where this comes from
Reported directly by Neurocrine Biosciences in its filing.
Tagged under the XBRL concept us-gaap:GainLossOnSaleOfBusiness.
The source filing: Neurocrine Biosciences’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 4:02 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0000914475-26-000026
| (in millions, except per share data) | Three Months Ended March 31, 2026 | 2025 |
|---|---|---|
| Research and development | 296.2 | 263.2 |
| Acquired in-process research and development | 21.2 | 0.1 |
| Selling, general, and administrative | 318.5 | 276.5 |
| Gain on sale of business, net of transaction costs | (28.6) | — |
| Total operating expenses | 621.1 | 549.0 |
| Operating income | 193.4 | 23.6 |
| Other income (expense): | ||
| Unrealized gain (loss) on equity investments | 25.3 | (30.6) |
Item 1. Financial Statements
FAQ
- What is Neurocrine Biosciences's gain (loss) on disposal of assets?
- Neurocrine Biosciences (NBIX) reported gain (loss) on disposal of assets of $28.6M in Q1 2026.
- What does gain (loss) on disposal of assets mean?
- Gains or losses recognized on the disposal of businesses, property, equipment, investments, or other assets at prices above or below their carrying value.
Ask your AI about Neurocrine Biosciences's gain (loss) on disposal of assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude